Key facts
- This page summarizes Skorpios Trust's Form 4 filing for Akero Therapeutics, Inc. (AKRO).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 05 Dec 2022, 15:36.
Skorpios Trust - 01 Dec 2022 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)
- Reporting relationship
- Former 10% owner
- Issuer ticker
- AKRO
- Reported as of
- 01 Dec 2022
- Net transaction value
- -$71,166,000
- SEC form
- 4
- Accepted by SEC
- 05 Dec 2022, 15:36:52 UTC
- Prior SEC filing
- 30 Jun 2021
- Next SEC filing
- 18 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Androulla Papadopoulou, Authorized Signatory on behalf of Skorpios Trust
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Skorpios Trust filed Form 4 for Akero Therapeutics, Inc. (AKRO) on 05 Dec 2022.
Change
- Previous filing in this sequence was filed on 30 Jun 2021.
- Current net transaction value: -$71,166,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKRO
transaction
Common Stock
Sale
- Transaction value
- $71,166,000
- Shares
- -1,636,000
- Change %
- -33%
- Price
- $43.50
- Shares after
- 3,271,829
- Date
- 01 Dec 2022
- Ownership
- See Footnote
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Skorpios Trust is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Blue Horizon Enterprise Ltd. ("Blue Horizon") is the direct owner of 2,346,298 shares of the issuer's common stock and Ezbon International Limited ("Ezbon") is the direct owner of 925,531 shares of the issuer's common stock. Skorpios Trust ("Skorpios") is the sole owner of each of Blue Horizon and Ezbon. Montrago Trustees Limited ("Montrago Trustees") is the corporate trustee of Skorpios Trust. Each of Blue Horizon and Ezbon disclaim beneficial ownership of the shares of the issuer's common stock held by the other, and each of Skorpios Trust and Montrago Trustees disclaim beneficial ownership of the issuer's securities except to the extent of their pecuniary interest therein.